AlzeCure Pharma (ALZCUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AlzeCure Pharma (ALZCUR) has a cash flow conversion efficiency ratio of -0.150x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.62 Million ≈ $-819.93K USD) by net assets (Skr50.66 Million ≈ $5.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ALZCUR market cap overview for the company's overall valuation and market capitalisation.
AlzeCure Pharma - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how AlzeCure Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AlzeCure Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AlzeCure Pharma ranked by their cash flow conversion efficiency. See how well can AlzeCure Pharma service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ilyang Pharm
KO:007570
|
0.009x |
|
AVer Information Inc
TW:3669
|
0.019x |
|
Technical Olympic S.A
AT:OLYMP
|
-0.002x |
|
Mahachai Hospital Public Company Limited
BK:M-CHAI
|
0.165x |
|
Samyang Tongsang Co. Ltd.
KO:002170
|
0.004x |
|
China Container Terminal Corp
TW:2613
|
0.063x |
|
Tae Kyung Ind
KO:015890
|
0.011x |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
-0.001x |
Annual Cash Flow Conversion Efficiency for AlzeCure Pharma (2017–2024)
The table below shows the annual cash flow conversion efficiency of AlzeCure Pharma from 2017 to 2024. View AlzeCure Pharma share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr26.18 Million ≈ $2.82 Million |
Skr-35.12 Million ≈ $-3.78 Million |
-1.341x | -1143.15% |
| 2023-12-31 | Skr23.77 Million ≈ $2.56 Million |
Skr3.06 Million ≈ $328.98K |
0.129x | +107.78% |
| 2022-12-31 | Skr60.48 Million ≈ $6.51 Million |
Skr-99.91 Million ≈ $-10.75 Million |
-1.652x | +22.89% |
| 2021-12-31 | Skr32.97 Million ≈ $3.55 Million |
Skr-70.64 Million ≈ $-7.60 Million |
-2.142x | -241.35% |
| 2020-12-31 | Skr110.75 Million ≈ $11.92 Million |
Skr-69.51 Million ≈ $-7.48 Million |
-0.628x | -127.15% |
| 2019-12-31 | Skr182.01 Million ≈ $19.59 Million |
Skr-50.28 Million ≈ $-5.41 Million |
-0.276x | -77.59% |
| 2018-12-31 | Skr233.17 Million ≈ $25.09 Million |
Skr-36.27 Million ≈ $-3.90 Million |
-0.156x | +4.26% |
| 2017-12-31 | Skr51.83 Million ≈ $5.58 Million |
Skr-8.42 Million ≈ $-906.23K |
-0.162x | -- |
About AlzeCure Pharma
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sl… Read more